<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25774" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuroacanthocytosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Feriante</surname>
            <given-names>Joshua</given-names>
          </name>
          <aff>UC Davis Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Feriante declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25774.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neuroacanthocytosis refers to a group of inherited genetic disorders resulting in a combination of misshapen red blood cells (acanthocytes) and progressive neurological decline. The neurological presentation can vary widely among diseases and can include shared characteristic features of movement disorders, neuropathy, psychiatric symptoms, neurocognitive degeneration, and seizures. This activity reviews the evaluation and treatment of neuroacanthocytosis and highlights the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of neuroacanthocytosis.</p></list-item><list-item><p>Review the appropriate evaluation of neuroacanthocytosis.</p></list-item><list-item><p>Outline the treatment options available for neuroacanthocytosis.</p></list-item><list-item><p>Summarize the importance of an interprofessional team to enhance the delivery of care and improve outcomes for patients affected by neuroacanthocytosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25774&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25774">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25774.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neuroacanthocytosis refers to a group of inherited genetic disorders resulting in a combination of misshapen red blood cells (acanthocytes) and progressive neurological decline.<xref ref-type="bibr" rid="article-25774.r1">[1]</xref> The neurological presentation can vary widely among diseases and can include shared characteristic features of movement disorders, neuropathy, psychiatric symptoms, neurocognitive degeneration, and seizures.<xref ref-type="bibr" rid="article-25774.r2">[2]</xref>&#x000a0;Specific diseases are many, including chorea-acanthocytosis (ChAc),<xref ref-type="bibr" rid="article-25774.r3">[3]</xref>&#x000a0;McLeod syndrome (MLS),<xref ref-type="bibr" rid="article-25774.r4">[4]</xref>&#x000a0;Huntington like-disease 2 (HDL2),<xref ref-type="bibr" rid="article-25774.r5">[5]</xref>&#x000a0;pantothenate kinase-associated neurodegeneration (PKAN),<xref ref-type="bibr" rid="article-25774.r6">[6]</xref><xref ref-type="bibr" rid="article-25774.r7">[7]</xref>&#x000a0;HARP Syndrome (considered part of the PKAN spectrum consisting of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration), abetalipoproteinemia (ABL),<xref ref-type="bibr" rid="article-25774.r8">[8]</xref>&#x000a0;hereditary hypobetalipoproteinemia (HHBL),<xref ref-type="bibr" rid="article-25774.r9">[9]</xref>&#x000a0;and aceruloplasminemia.<xref ref-type="bibr" rid="article-25774.r10">[10]</xref><xref ref-type="bibr" rid="article-25774.r11">[11]</xref>&#x000a0;The two core conditions are chorea-acanthocytosis and McLeod Syndrome. Each neuroacanthocytosis disorder is extremely rare, with a prevalence of less than 1 to 3 per 1,000,000 individuals for PKAN or fewer than 100 cases ever reported in the case of ABL.</p>
      </sec>
      <sec id="article-25774.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Neuroacanthocytosis syndromes are caused by a variety of genetic mutations that are inherited in several different patterns, with the most common being autosomal recessive (see Tables 1 &#x00026; 2). Other syndromes such as McLeod syndrome are inherited in an X-linked recessive pattern, whereas Huntington like-disease 2 and hereditary hypobetalipoproteinemia are inherited in autosomal dominant and codominant patterns, respectively. HDL2 directly results from trinucleotide expansions of JPH3 very similarly to Huntington disease with patients experiencing intergenerational disease anticipation based on the extent of genetic expansion. Many of these diseases vary in genetic penetrance and phenotypic manifestations.<xref ref-type="bibr" rid="article-25774.r3">[3]</xref><xref ref-type="bibr" rid="article-25774.r4">[4]</xref><xref ref-type="bibr" rid="article-25774.r5">[5]</xref><xref ref-type="bibr" rid="article-25774.r6">[6]</xref><xref ref-type="bibr" rid="article-25774.r8">[8]</xref><xref ref-type="bibr" rid="article-25774.r9">[9]</xref><xref ref-type="bibr" rid="article-25774.r10">[10]</xref></p>
      </sec>
      <sec id="article-25774.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Each neuroacanthocytosis syndrome is exceedingly rare (see Table 1). Several populations have been identified as having higher prevalence compared to the global population. Examples include&#x000a0;HDL2 demonstrating increased reported cases among individuals of African heritage and PKAN occurring more often in small pockets in the Netherlands and the Dominican Republic.<xref ref-type="bibr" rid="article-25774.r5">[5]</xref></p>
      </sec>
      <sec id="article-25774.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of these syndromes is unique to each and can vary widely in phenotypic disease manifestation (see Table 2). The direct cellular mechanisms of several syndromes such as PKAN, aceruloplasminemia, and diseases of lipoproteins are understood and described in the current literature. These syndromes tend to have better outcomes either due to milder disease progression or treatment modalities that prevent significant mortality and morbidity.<xref ref-type="bibr" rid="article-25774.r6">[6]</xref><xref ref-type="bibr" rid="article-25774.r8">[8]</xref><xref ref-type="bibr" rid="article-25774.r9">[9]</xref><xref ref-type="bibr" rid="article-25774.r10">[10]</xref>&#x000a0;Other diseases such as ChAc, MLS, and HDL2 are not well understood despite the identification of involved genes.<xref ref-type="bibr" rid="article-25774.r3">[3]</xref><xref ref-type="bibr" rid="article-25774.r4">[4]</xref><xref ref-type="bibr" rid="article-25774.r5">[5]</xref> These diseases tend to be much more chronically debilitating and are not uniformly responsive to&#x000a0;attempted&#x000a0;treatments that have been sparsely reported.</p>
      </sec>
      <sec id="article-25774.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Nearly all patients affected by neuroacanthocytosis syndromes will experience the eventual onset of progressive abnormalities in movement (usually ataxia or hyperkinetic movements) with a neurocognitive decline and behavioral changes (see Table 3). Each specific disease, however, may present with symptoms and comorbidities unique to the disease.&#x000a0;If&#x000a0;the clinician possesses significant clinical suspicion of a neuroacanthocytosis syndrome, a thorough physical exam is required. This would include a complete physical and neurological examination, including reflexes, cranial nerves, gait, muscle strength, and mental status exams.</p>
        <p>A clear history of progressive neurological, neuromuscular, or neuropsychiatric symptoms that are not consistent with other&#x000a0;more common diseases plays an integral role in identifying these rare syndromes as possible diagnoses. The acquisition of prior records, family history, collateral history, and any prior genetic testing may prove instrumental in establishing accurate differential diagnoses and choosing clinically appropriate diagnostic modalities for further evaluation.</p>
      </sec>
      <sec id="article-25774.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>For many of these syndromes, the clinical symptoms will often prompt the use of additional diagnostic modalities that are instrumental in establishing a correct diagnosis (see Table 4). Such modalities include magnetic resonance imaging (MRI), or computed tomography (CT) scans to assess neurological involvement in the&#x000a0;cerebral or spinal nervous tissues. Additionally, laboratory testing of serum samples may be useful in ruling out some diseases while providing confirmatory data for others, as in the case of the diseases of lipoproteins (ABL and HHBL) or aceruloplasminemia. For most neuroacanthocytosis syndromes, there are either no clear diagnostic criteria (e.g., ChAc, ABL, and HHBL) or genetic testing to identify diseases that may otherwise be indistinguishable from other syndromes (e.g., HDL2).</p>
      </sec>
      <sec id="article-25774.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no cure or definitive treatment for several of the neuroacanthocytosis syndromes, such as ChAc and MLS (see Table 5).<xref ref-type="bibr" rid="article-25774.r12">[12]</xref> With the exception of ABL, HHBL, and aceruloplasminemia, the goals of management generally are to:</p>
        <p>1) Treat symptomatically</p>
        <p>2) Slow the development of progressive symptoms</p>
        <p>3) Evaluate for and prevent where possible serious causes of morbidity and mortality such as ophthalmic involvement,&#x000a0;metabolic/hormonal imbalances, seizures, cardiac involvement, and status dystonicus.</p>
        <p>Interprofessional&#x000a0;treatment teams have been advocated as the ideal approach in caring for patients who likely have complex and significant symptoms that run the gamut of neurological to psychiatric to multiple organ systems.<xref ref-type="bibr" rid="article-25774.r12">[12]</xref></p>
        <p>Consultation by medical specialists in neurology, psychiatry, neuropsychiatry, ophthalmology, or clinical genetics may be appropriate in identifying, evaluating, and managing patients diagnosed with neuroacanthocytosis syndromes (see Table 6).</p>
      </sec>
      <sec id="article-25774.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for these rare syndromes are many and sometimes may be indistinguishable from other disease entities without the appropriate radiological, laboratory, or genetic workup (see Table 7).</p>
      </sec>
      <sec id="article-25774.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Due to the extreme rarity of these syndromes, there have been no randomized control trials or experimental treatment studies assessing the efficacy of diagnostic or treatment modalities.<xref ref-type="bibr" rid="article-25774.r12">[12]</xref><xref ref-type="bibr" rid="article-25774.r13">[13]</xref><xref ref-type="bibr" rid="article-25774.r14">[14]</xref>&#x000a0;Information regarding diagnostic criteria and possible treatments have been largely developed from the aggregation of case reports and case series.<xref ref-type="bibr" rid="article-25774.r12">[12]</xref></p>
      </sec>
      <sec id="article-25774.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>There are several side effects to keep in mind for several specific syndromes and their associated management (see Table 5). For example, antiepileptic drugs (AEDs) such as carbamazepine and lamotrigine should be avoided in patients with ChAc due to the worsening of involuntary movements.<xref ref-type="bibr" rid="article-25774.r3">[3]</xref> Conversely, long-term use of benzodiazepines should be avoided as an AED in patients with McLeod syndrome due to potential negative effects on the neuromuscular system. Additionally, dopamine antagonists or tetrabenazine should be avoided due to increased risk of extrapyramidal symptoms (EPS) in MLS patients.<xref ref-type="bibr" rid="article-25774.r4">[4]</xref></p>
        <p>Another consideration for MLS patients is to avoid heterologous blood product transfusions due to an increased risk of adverse transfusion reactions. Case reports have suggested avoiding alpha-tocopherol and idebenone in treating the neuromuscular symptoms of patients with PKAN due to anecdotal evidence suggesting worsening of symptoms.<xref ref-type="bibr" rid="article-25774.r6">[6]</xref> Finally, patients should avoid iron supplementation or other sources of exogenous iron due to the iron accumulation inherent in the disease.<xref ref-type="bibr" rid="article-25774.r10">[10]</xref></p>
      </sec>
      <sec id="article-25774.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for these syndromes is variable. Syndromes such as ChAc, MLS, typical PKAN, and HDL2 are known to be chronic and progressive, often resulting in complications of dysarthria such as malnutrition and aspiration pneumonia&#x000a0;with eventual death (see Table 8). In some cases, complicating symptoms such as seizures, cardiac arrhythmias, cardiomyopathy, and status dystonicus may cause premature death. On the other hand, the mortality and progression of aceruloplasminemia, ABL, and HHBL are heavily influenced by appropriate management with chelating agents and fat-soluble vitamin supplementation (respectively) with patients enjoying a typical lifespan if managed appropriately.<xref ref-type="bibr" rid="article-25774.r8">[8]</xref><xref ref-type="bibr" rid="article-25774.r9">[9]</xref><xref ref-type="bibr" rid="article-25774.r10">[10]</xref></p>
      </sec>
      <sec id="article-25774.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Many of the complications arising from neuroacanthocytosis syndromes derive from neuromuscular deficits or neurocognitive decline (see Table 3). Neuromuscular symptoms such as chorea, ataxia, myopathy, dystonia, loss of dorsal column, or spinocerebellar spinal tracts can result in gait disturbances and inability to participate in ADLs. Additional progressive cognitive deficits or personality changes (including increased impulsivity, aggression, or psychiatric symptoms) can further complicate care for patients diagnosed with a neuroacanthocytosis syndrome. Several complications can be life-threatening, including seizures, cardiac arrhythmias, cardiomyopathy, status dystonicus, and psychiatric comorbidities such as suicidality.</p>
        <p>Ophthalmological complications such as retinal degeneration and retinopathy are commonly described in cases of PKAN, ABL, HHBL, and aceruloplasminemia. In the case of several metabolically driven diseases such as ABL, HHBL, and aceruloplasminemia, multiple organ systems can be involved resulting in anemia, diabetes mellitus, cardiomegaly, hepatosplenomegaly, and hypothyroidism.</p>
      </sec>
      <sec id="article-25774.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Genetic counseling plays an important role in the management as well as appropriate evaluation and education for both the patient and involved family members. Consultation with a genetic counselor and clinical geneticist can provide important clinical information such as genotypic and phenotypic characteristics of the disease, possible disease progression, and the likelihood of disease occurring in relatives or offspring.<xref ref-type="bibr" rid="article-25774.r1">[1]</xref></p>
      </sec>
      <sec id="article-25774.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Recent literature advocates&#x000a0;interprofessional team-based care as the ideal approach in caring for patients diagnosed with neuroacanthocytosis syndromes due to the severity and chronic progression of symptoms as well as possible development of severe medical comorbidity.<xref ref-type="bibr" rid="article-25774.r12">[12]</xref>&#x000a0;Such a care team would likely consist of the patient's primary care clinician, neurologist, clinical geneticist (or genetic counselor), and several other therapeutic modalities (see Table 5). Providers may seek additional care in consultation with specialists in psychiatry, ophthalmology, and cardiology in diseases such as MLS, PKAN, and ABL/HHBL. The extreme rarity of these syndromes significantly limits evidence-based treatments. Patients with these syndromes&#x000a0;may require involved and prolonged team-based care to improve symptoms and prevent the development of serious medical complications.</p>
      </sec>
      <sec id="article-25774.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25774&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25774">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/neuroacanthocytosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25774">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25774/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25774">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25774.s17">
        <fig id="article-25774.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Table 1: Epidemiology of Neuroacanthocytosis Syndromes
Table 2: Genetics of Neuroacanthocytosis Syndromes Contributed by Joshua Feriante DO, MBA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Neurocanthocytosis__Tables__1__and__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25774.s18">
        <fig id="article-25774.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Table 3: Clinical Manifestations of Neuroacanthocytosis Syndromes Contributed by Joshua Feriante DO, MBA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__3__Clinical__Manifestations__of__Neuroacanthocytosis__Syndromes" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25774.s19">
        <fig id="article-25774.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Table 4: Diagnostic Testing for Neuroacanthocytosis Syndromes Contributed by Joshua Feriante DO, MBA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__4__Diagnostic__Testing__for__Neuroacanthocytosis__Syndromes" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25774.s20">
        <fig id="article-25774.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Table 5: Management, Preventive Measures, and Multi-disciplinary Team Involvement for Neuroacanthocytosis Syndromes
Table 6: Preventive Measures and Multi-disciplinary Team Involvement for Neuroacanthocytosis Syndromes Contributed by Joshua Feriante DO, MBA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Neurocanthocytosis__Table__5__and__6" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25774.s21">
        <fig id="article-25774.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Table 7: Differential Diagnoses for Neuroacanthocytosis Syndromes
Table 8: Prognoses of Neuroacanthocytosis Syndromes Contributed by Joshua Feriante DO, MBA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Neurocanthocytosis__Table__7__and__8" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25774.s22">
        <title>References</title>
        <ref id="article-25774.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Danek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Neuroacanthocytosis syndromes.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2011</year>
            <month>Oct</month>
            <day>25</day>
            <volume>6</volume>
            <fpage>68</fpage>
            <pub-id pub-id-type="pmid">22027213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Patkar</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>A case of McLeod phenotype of neuroacanthocytosis brain MR features and literature review.</article-title>
            <source>Neuroradiol J</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-6</page-range>
            <pub-id pub-id-type="pmid">23859162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Peikert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dobson-Stone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rampoldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miltenberger-Miltenyi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Neiman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Camilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Danek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title><italic>VPS13A</italic> Disease</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2002</year>
            <month>6</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">20301561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jung</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Danek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Peikert</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>McLeod Neuroacanthocytosis Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2004</year>
            <month>12</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">20301528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Anderson</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <chapter-title>Huntington Disease-Like 2</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2004</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">20301701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gregory</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayflick</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <chapter-title>Pantothenate Kinase-Associated Neurodegeneration</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2002</year>
            <month>8</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">20301663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Razmeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Habibi</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Orooji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alizadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moradiankokhdan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Razmeh</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pantothenate kinase-associated neurodegeneration: Clinical aspects, diagnosis and treatments.</article-title>
            <source>Neurol Int</source>
            <year>2018</year>
            <month>Mar</month>
            <day>30</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>7516</fpage>
            <pub-id pub-id-type="pmid">29844889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Burnett</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <chapter-title>Abetalipoproteinemia</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">30358967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welty</surname>
                <given-names>FK</given-names>
              </name>
            </person-group>
            <article-title>Hypobetalipoproteinemia and abetalipoproteinemia.</article-title>
            <source>Curr Opin Lipidol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-8</page-range>
            <pub-id pub-id-type="pmid">24751931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Miyajima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hosoi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <chapter-title>Aceruloplasminemia</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>8</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">20301666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Busti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lira Zidanes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castagna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Girelli</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Aceruloplasminemia: A Severe Neurodegenerative Disorder Deserving an Early Diagnosis.</article-title>
            <source>Front Neurosci</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>325</fpage>
            <pub-id pub-id-type="pmid">31024241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Management of Neuroacanthocytosis Syndromes.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>346</fpage>
            <pub-id pub-id-type="pmid">26504667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vroegindeweij</surname>
                <given-names>LHP</given-names>
              </name>
              <name>
                <surname>Boon</surname>
                <given-names>AJW</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JHP</given-names>
              </name>
              <name>
                <surname>Langendonk</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2020</year>
            <month>Apr</month>
            <day>25</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>105</fpage>
            <pub-id pub-id-type="pmid">32334607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25774.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Junaid</surname>
                <given-names>SZS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Abetalipoproteinemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30020727</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
